Back to Search
Start Over
Molecular remission using low-dose immunotherapy for relapsed refractory Philadelphia chromosome-positive precursor B-cell acute lymphoblastic leukemia post-allogeneic stem cell transplant.
- Source :
-
Future science OA [Future Sci OA] 2019 Apr 12; Vol. 5 (5), pp. FSO380. Date of Electronic Publication: 2019 Apr 12 (Print Publication: 2019). - Publication Year :
- 2019
-
Abstract
- Adults with relapsed/refractory acute lymphoblastic leukemia have a poor prognosis. While current immunotherapies are promising, they are toxic, with graft-versus-host disease a major complication of allogeneic therapy. Here, we report a patient with high-risk relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (ALL) following chemotherapy induction, matched related donor allogeneic hematopoietic stem cell transplantation (allo-HCT), donor lymphocyte infusion and two tyrosine kinase inhibitors. The patient achieved a complete molecular and cytogenetic remission with minimal adverse events or evidence of GVHD following recombinant human IL-2 (rIL-2), in combination with a tyrosine kinase inhibitor (TKI). There was a ninefold increase in natural killer (NK) cell activity and natural killer T cells (NKT) cells (CD2 <superscript>+</superscript> CD26 <superscript>+</superscript> ). Personalized low dose recombinant human IL-2-mediated NK cell stimulation represents an effective, nontoxic immunotherapy administered in the outpatient setting for relapsed acute lymphoblastic leukemia and warrants further investigation.<br />Competing Interests: Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Details
- Language :
- English
- ISSN :
- 2056-5623
- Volume :
- 5
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Future science OA
- Publication Type :
- Report
- Accession number :
- 31245042
- Full Text :
- https://doi.org/10.2144/fsoa-2019-0009